# Clinical Trial Findings on Short-Term Low-Dose Cannabidiol and Glucose Tolerance > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/short-term-low-dose-cannabidiol-glucose-tolerance-study/ > **Published:** 2026-04-18T11:25:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:01:02-04:00 > **Clinical Summary:** Explore the short-term low-dose cannabidiol glucose tolerance pilot study results in adults with overweight or obesity and its effects on metabolism and gut health. --- #### Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not produce measurable improvements in glucose tolerance, gut microbiome composition, or inflammatory markers in sedentary adults with overweight or obesity. While animal studies and epidemiological data have suggested a possible protective role for cannabinoids against type 2 diabetes, these findings indicate that brief, low-dose CBD use alone is unlikely to replicate those effects in humans. Larger studies using higher doses and longer treatment durations are needed before any clinical conclusions can be drawn. ### #5 Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study. **Citation:** Ewell Taylor R et al. *Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.* Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). 2026. PMID: 41167732. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 12 Design: 5 Journal: 1 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 **Abstract:** INTRODUCTION: Epidemiological data indicate that regular users of cannabis products may be protected from type 2 diabetes, although the mechanism is not understood. Observations from animal studies suggest that the cannabinoid, cannabidiol (CBD) may protect/improve glucose tolerance; an effect that may be partially mediated by favorable modifications to the gut microbiome. The aims of the current pilot project were to gain initial insight into the influence of short-term CBD ingestion on oral glucose tolerance, the gut microbiome, and inflammation in sedentary adults with overweight or obesity and free from diabetes. MATERIALS AND METHODS: Using a randomized, double-blind, repeated measures, parallel design, oral glucose tolerance was determined in 16 adults (6 males, 10 females) prior to and following 4 weeks of daily ingestion of either placebo or CBD (30 mg every 12 h). Fecal samples were collected at baseline and post-intervention. RESULTS: Compared with placebo, CBD did not influence glucose tolerance (Matsuda Index: placebo-pre 7.6 [5.5], placebo-post 10.1 [5.5], vs. CBD-pre 11.7 [7.9], and hCBD-post 10.1 [10.2]; median [interquartile range]; p > 0.05). Characteristics of the gut microbiome or inflammation were not appreciably modified by CBD or placebo. DISCUSSION: Short-term daily ingestion of low-dose CBD did not appear to favorably modify glucose tolerance in sedentary adults with overweight or obesity. It is possible that CBD may not account for the previously reported protection from type 2 diabetes bestowed to regular users of cannabis products.  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41167732/)[DOI ↗](https://doi.org/10.1177/25785125251391085) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol Glucose Tolerance Effects in Obesity](https://cedclinic.com/cannabidiol-glucose-metabolism-obesity-effects-study/) Detailed exploration of cannabidiol’s impact on glucose tolerance specifically in obese adults, highlighting clinical findings and metabolic implications. [Read More](https://cedclinic.com/cannabidiol-glucose-metabolism-obesity-effects-study/) [Cannabis Research: Cannabidiol’s Impact on Glucose Tolerance & Gut Microbiome in Obese Adults](https://cedclinic.com/cannabidiol-impact-glucose-tolerance-obese-adults/) Comprehensive research review on how cannabidiol influences glucose tolerance and gut microbiome composition in adults with obesity. [Explore Research](https://cedclinic.com/cannabidiol-impact-glucose-tolerance-obese-adults/) [Cannabidiol Glucose Tolerance Study Evidence Based](https://cedclinic.com/cannabidiol-glucose-tolerance-study/) Evidence-based analysis of cannabidiol’s role in glucose tolerance, summarizing clinical trial data and metabolic health outcomes. [Learn More](https://cedclinic.com/cannabidiol-glucose-tolerance-study/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Clinical%20Trial%20Findings%20on%20Short-Term%20Low-Dose%20Cannabidiol%20and%20Glucose%20Tolerance&url=https%3A%2F%2Fcedclinic.com%2Fshort-term-low-dose-cannabidiol-glucose-tolerance-study%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fshort-term-low-dose-cannabidiol-glucose-tolerance-study%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Clinical%20Trial%20Findings%20on%20Short-Term%20Low-Dose%20Cannabidiol%20and%20Glucose%20Tolerance%20https%3A%2F%2Fcedclinic.com%2Fshort-term-low-dose-cannabidiol-glucose-tolerance-study%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).